Background: Restrictive cardiomyopathy (RCM) is a rare heart disease associated with mutations in sarcomeric genes and with phenotypic overlap with hypertrophic cardiomyopathy. There is no approved therapy. Here, we explore the potential of an interfering RNA (RNAi) therapeutic for a human sarcomeric mutation in MYL2 causative of restrictive cardiomyopathy in a mouse model. Methods: AAV9-M7.8L
Introduction
Restrictive cardiomyopathy (RCM) is a cardiac disease caused by autosomal dominant variants in genes encoding proteins of the cardiac sarcomere. With phenotypic overlap with hypertrophic cardiomyopathy (HCM), pathogenic variants causative for both conditions are found in cardiac myosin, the enzyme that generates mechanical forces required for muscle contraction through ATP hydrolysis. Cardiac myosin is a hexameric protein complex with two myosin heavy chains, either α-MHC encoded by MYH6 (predominant in adult rodent ventricle) or β-MHC encoded by MYH7 (predominant in adult human ventricle) and four light chains: two regulatory light chains (RLC) encoded by MYL2 and two essential light chains (ELC) encoded by MYL3 respectively. Mutations in cardiac myosin alter the mechanical force, redox states and cellular signals in a dominant negative manner leading to disease pathology. The mechanisms by which these mutations alter cardiac function and lead to clinically diverse phenotypes are not fully understood.
Restrictive cardiomyopathy causes significant morbidity and mortality. Although it can be readily detected, medical treatment remains largely palliative and often limited by adverse effects. Currently, there is no FDA-approved therapy that targets the root cause of the disease. While technology such as precise genome editing has been tested in embryos at risk for HCM, 1 challenges remain to design tools effective in postimplantation humans. One report describes silencing of one variant in the mouse alpha myosin heavy chain. 2 Challenges remain in treating cases where only a single nucleotide distinguishes a healthy gene from one that confers a severe disease phenotype.
Herein, we present our approach to selective allele specific silencing 3 of the human RCM mutation p.N47K (asparagine to lysine) of the regulatory light chain (RLC) encoded by MYL2 in a humanized transgenic mouse model using an Adeno-Associated Virus-RNA interference (AAV-RNAi) approach (Figure 1 ). This variant was reported in humans 4 and subsequently in mouse models. 5, 6 We demonstrate here that RNAi treatment of humanized RLC-47K mutant mice ameliorates disease phenotypes by specifically reducing the cardiac expression of the mutated allele, hypertrophic biomarkers, and intramyocardial fibrosis. Isolated cardiomyocytes from treated animals showed normalization of contraction and relaxation dynamics, with partial restoration of calcium reuptake dynamics. Cardiac genome-wide transcriptome profiling demonstrated a reduction in the hypertrophic program without significant off-target effects.
Methods
The data, analytic methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure. Material will be available at GEO/NCBI accession number GSE125732. For full methods, please see supplementary materials.
Small interfering RNA (siRNA) design Twenty one siRNAs were designed to target the 47K variant of the MYL2 gene. Highlighted with red shows the variant in different positions in all siRNA molecules (Figure 2A) . siRNAs are 21 mer duplexes and contain standard modifications such as alternated 2-O-Methyl modifications to increase backbone resistance against endonucleases, 2 nucleotide overhangs at the 3' end and a phosphate group at the 5'end.
Mismatched pairing was also introduced (Support Figures 1 and 2) . siRNAs were synthesized by the Protein and Nucleic Acid Facility of Stanford University.
Short hairpin RNA (shRNA) design shRNAs were designed based on the nucleotide sequence of the sense strand of MYL2 siRNAs. Sense and antisense strands are 19 mer length connected by a 8 bp loop sequence (Hind III restriction site) and contain Bbs I restriction sites for cloning (Support Figure 3 ). shRNAs were cloned in self complementary pAAV RSVp-Cerulean plasmid in the BbsI restriction sites and their expression is drive by H1 promoter. Cloning was confirmed by HindIII/NheI double digestion and sequencing (Support Figure 3 ).
Allele quantitative polymerase chain reaction (RT-PCR)
Total RNA was isolated (miRNeasy Qiagen). RNA analysis was carried out using Bioanalyzer for size distribution and quality control and High Sensitivity (HS) Qubit for RNA concentration. cDNA synthesis (Applied Biosystems) was prepared for allele quantitative PCR. For mutant detection and wild type discrimination the following reaction was carried out in 20 ul volume: Mutant specific Forward (0.5 um) (18mer=GGCTTCATTGACAAGAAA) Reverse primer (0.5 um) (TTCCTCAGGGTCCGCTCCCTTA), wild-type specific blocker 1 (5 um) (TGACAAGAACGATCTGAGA-PO4), MYL2 hydrolysis probe containing 6-FAM at the 5'end and TAMRA at the 3'end (5'-TGGATGAAATGATCAAGGAGGCTCCG- siRNAs and shRNAs screening HEK293 cells were co-transfected with plasmids pMYL2-47N-GFP (wild type) and pMYL2-47K-mCherry (mutant). Lipofectamine LTX (Invitrogen) was used to mediate transfection of 100 ng of each plasmid following the manufacturer's instructions and G418 antibiotic (1000ug/ml) to generate stable transfected cell lines. Individual clones expressing GFP and mCherry proteins were isolated by FACS. Sorting was performed on an LSRII.UV: S10RR027431-01 instrument in the Stanford Shared FACS Facility using NIH S10 shared instrument Grant. (Support Figure 7 ).
Single nucleotide variant (SNV) analysis
SNV analysis of RLC transgenic mice was carried out using pyrosequencing. To identify the normal and mutant variants, the following primers were used: MYL2-Pyrosequencing Forward:
ACAGGGATGGCTTCATTGACA, MYL2-Biotin-pyrosequencing Reverse: O-TTCCTCAGGGTCCGCTCCCTTA and MYL2 sequencing primer GGCTTCATTGACAAGAA. AmpliTaq Gold (Applied biosystems) for PCR amplification and SNP analysis. (Support Figure 8 ). In vivo AAV9 M7.8L transduction of RLC-N47K transgenic mice RLC transgenic mice were injected via the jugular vein at different ages. For the young group, 1x10 12 genomic titer of AAV9 expressing M7.8L shRNA and non-expressing shRNA (control) was injected. For the neonatal group, 25ul of virus were injected (3x10 11 viral particles). A second AAV9 containing eGFP and luciferase was used as control to track the virus expression over time (Support Figure 9 ). Traction Force Microscopy of MYL2-N47K Neonatal cardiomyocytes Cells were cultured on 2000 mm 2 rectangular laminin (BD Biosciences) patterns with an aspect ratio of 5:1 on polyacrylamide (PA) substrates to generate an elongated shape and sarcomeric organization, to encourage contraction along their main axis and to present aligned sarcomere organization 7 . Gels were fabricated as reported elsewhere 8 . We mixed PA gel components (12% Acrylamide -0.15% N, Nmethylene-bis-acrylamide) in DI water and added 50 µl of solution on clean coverslips pretreated with aminopropyltriethoxysilane and glutaraldehyde. Polymerization occurred after placing a coverslip with stamped patterns on its surface on top of the gel component. Ammonium persulfate was used as a catalyst for gel polymerization and N,N,N,N-tetramethylethylenediamine as an initiator. Coverslips were patterned and transferred to gels according to an already published method 9 and soft lithography was utilized to fabricate polydimethylsiloxane (Sylgard) microstamps. Microstamps were flooded with 10 mg/mL laminin for 30 minutes and dried under a stream of N2 and then placed on top of a pre-cleaned glass coverslip to be placed on top of the gel solution. Once in culture, videos of contractile cardiomyocytes were acquired in brightfield with a high speed CCD camera (Orca-R2 Hamamatsu). We measured the contractile shortening of cardiomyocytes and beat rate with custom ImageJ and Matlab scripts.
Human transgenic RLC-N47K mice

Measurement of intracellular calcium transients and contractile function
Intracellular calcium transients of left ventricular, Fura-2 AM loaded, rod-shaped cardiomyocytes were recorded while simultaneously measuring sarcomere length using the IonOptix Myocyte Calcium and Contractility Recording System (Milton, MA). Approximately 100-150 left ventricular cardiomyocytes were loaded onto the mTCII cell chamber and suffused with 37°C cardiomyocyte pacing buffer at a 0.5mL/min flow-rate. The chamber was paced at 1.0 Hz and 15 V at a duration of 5 ms. Inclusion criteria for cardiomyocyte selection consisted of completely isolated single cells with rod-shaped morphology, resting sarcomere length 1.7-1.85μm, uniform contractility, and absence of arrhythmia. Free intracellular calcium levels were recorded using the 340/380 nm excitation-510 nm emission ratio and IonWizard 6.0 ratiometric fluorescence software was used to determine the the maximal calcium reuptake velocity, time to maximal calcium reuptake velocity, calcium transient reuptake decay rate (tau), and relaxation T50. Simultaneous sarcomere shortening measurements using IonoWizard 6.0 cell dimensioning data acquisition software allow for determination of maximal velocity of sarcomere shortening (-dL/dtmax) and relaxation (+dL/dtmax), time to -dL/dtmax and +dL/dtmax, relaxation tau decay rate, and shortening and relaxation T50, 75, 90. Alignment of sequencing reads to the mouse genome. The 100-base long single-end reads were assessed with FASTQC, leading and trailing bases with quality less than 5 were trimmed and reads with a windowed-average (window of size 5) quality of less than 20 were filtered out. The remaining reads were then aligned to the mouse reference genome (mm9) using the STAR aligner with the maximum allowed number of multiple alignments per read set to 10.
Maximum exercise treadmill testing
Estimation of gene expression.
We used the Cufflinks package to quantify gene expression from the aligned reads. Since we wanted to quantify known genes, we did not assemble transcripts de novo and instead relied on the mm9 gene models, using Cuffquant with default parameters to quantify expression in FPKM. Differential expression was performed with Cuffdiff, grouping replicates together.
Gene interaction networks
We used STRING to extract pairs of gene-gene interactions focusing on protein-protein interactions and obtaining confidence scores, shown in Figure 5H . The genes in the network are colored by their fold change value, which are now given in supplementary table II. We chose the genes with the highest or lowest fall change that had a significant, Benjamini-Hochberg corrected independent t-test p-value. To ease visualization in the heatmap and in the network, we chose the top 30 up-regulated and top 30 downregulated genes. Additionally, for reference, we now included the following genes (See supplementary   Table II and Table III) , which are known to be involved in HCM, although not all their p-values were significant in our analysis. (1) 
Statistical analysis
Standard deviation (SD) was used for error bars and unpaired t-test for two set comparison for Figures
Results
Selection of M7.8L
Gene silencing studies using RNA interference molecules were carried out on the human RCM mutation p.N47K (p.Asp47Lys) of the regulatory light chain (RLC) encoded by the MYL2 gene. To explore the dynamics of position-specific mismatch of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), we developed a HEK293 cell model stably double-transfected with plasmids containing the normal and mutant alleles fused to green (GFP) and mCherry fluorescent reporters respectively expressing same amount of both alleles. siRNAs and shRNAs were designed to specifically target the MYL2-47K human mutation ( Figure 2A ). siRNAs were designed as 21mer duplexes with a phosphate group at the 5' end of the antisense strand and alternated 2'-O-methyl (2'OMe) residues to provide nuclease stabilization to evade degradation (Support Figure 1 ). These modifications also reduce activation of the interferon response 10, 11 . With these standard modifications, we screened HEK cells transfected with siRNAs that targeted MYL2-47K by FACS. As shown, M5, M6 and M7 siRNAs decreased the expression of MYL2-47K-mCherry (mutant allele) from 50-65% and the MYL2-47N-eGFP (normal allele) by 10% ( Figure 2B ).
To increase specificity and efficacy of the small RNA molecules, chemical modifications were made on the M5 (mM5-1, mM5-2 and mM5-3) and M7 (mM7-1, mM7-2, mM7-3 and mM7-4) siRNAs (Support Since stable long-term treatment is our ultimate goal, shRNAs analogous to the best performing siRNAs were designed and cloned in a self-complementary adeno-associated (scAAV) plasmid vector (Support Table I ) in combination with digital droplet PCR (ddPCR) to allow allele discrimination. M7.8L shRNA reduced mRNA transcripts for the 47K mutant allele by 50% and the 47N normal allele by 10% ( Figure 2E ). Single nucleotide variant (SNV) analysis of transcripts from shRNA transfected cells showed 40% knockdown of the mutant variant without affecting the normal variant ( Figure   2F ). After identifying and selecting the best shRNA targeting the 47K mutation (M7.8L) we prepared a selfcomplementary AAV for transduction ex vivo of neonatal cardiomyocytes and in vivo of transgenic mice.
Effects of AAV9-M7.8L in neonatal cardiomyocytes
Ex-vivo gene silencing studies of the RLC-47K mutation were carried out in neonatal cardiomyocytes (NCM) isolated from three days old transgenic mice containing both human alleles: RLC-47N (normal) and RLC-47K (mutant) expressed at a 1:1 ratio according to pyrosequencing (Support Figure 8 ). NCM from each single neonatal mouse were cultured in a 48-well plate and transduced with 1x10 6 infectious titer of AAV9 expressing M7.8L shRNA and incubated for 4-5 days. Cells showed 85% transduction efficiency using cerulean reporter expression ( Figure 2G ). Transduced cells were subjected to growth on micro patterning devices to explore the force dynamics of the cells and harvested for qPCR and pyrosequencing analysis 14 . The RLC-47K mutant allele was decreased by ~40% following treatment with M7.8L, while the RLC-47N normal allele decreased by 15% ( Figure 2H -I), however no significant change in maximal contraction velocity nor maximum displacement was observed ( Figure 2J-K) , perhaps due to the short duration of silencing.
AAV9-M7.8L therapy in the humanized MYL2-47K mouse restored normal phenotype Pre-clinical animal studies were carried out in two different groups of RLC transgenic mice: i) an "adolescent" group (treatment started at 2 months old) and ii) a "neonatal group" (treatment started at 3 days old). Each group included three different genotypes: RLC-47N (human normal allele transgenic, wtTg), RLC-47K (human mutant allele transgenic, mutTg) and RLC-N47K (contains both human normal and human mutant transgenes/double transgenic, dTg). Before (adolescent group) and after (both groups) AAV9-M7.8L treatment, each animal was subjected to treadmill exercise with metabolic cart to measure exercise capacity via maximal oxygen uptake (VO2max), and echocardiography for heart function. After sacrifice, single cell studies were performed to measure contraction, relaxation, and calcium dynamics.
Mice in the 'adolescent' transgenic group were each treated with a single injection of AAV-M7.8L at two months of age and followed for four months. The double transgenic (dTg) mice in this group exhibited impaired exercise capacity and low survival. We postulate that this may relate to the overall burden of transgenes in these animals. Natriuretic peptide and MYH7 expression was increased greatly in these animals (data not shown). In the mutant transgenic group (mutTg), M7.8L RNAi reduced the expression of the mutant allele by 42% (Support Figure 10a) . These findings were consistent with echocardiographic studies and single cell studies that showed limitation of increase in left ventricular mass. Natriuretic peptides (ANP and BNP) and MYH6 did not change in the mutTg group whereas MYH7 expression levels were decreased by 50% (Support Figure 10b-c) . Collagen deposits were quantified by trichrome staining and no change was observed either in the adolescent treated mutant transgenic (Support Figure 10d) .
The neonatal transgenic group, where treatment with a single injection was given at three days of age, showed silencing of the mutant allele by 65% in mutTg mice assessed at 4 months of age ( Figure 3A) .
Quantitative PCR of cerulean fluorescent protein reporter expression confirmed effective delivery to the heart (cycle threshold CT=20-22 vs Undetermined cycle threshold in untreated mice). Expression of hypertrophic markers ANP, BNP and MYH7 were also significantly reduced by 90%, 85% and 65% respectively ( Figure 3B , 3C and 3D), while MYH6 was significantly upregulated ( Figure 3E) . Heart weight and left ventricular mass were also attenuated ( Figure 3F -G) as well as collagen deposits ( Figure   3H -I).
Off-target delivery of M7.8L to the lungs and the liver was also assessed via quantitative PCR in post mortem specimens from these mice. In contrast with the marked shRNA expression in the heart, consistent with prior data for AAV9, only modest expression was seen in liver and minimal expression in lung and kidney of treated animals ( Figure 3J) . These findings suggest that early treatment with M7.8L RNAi can prevent RCM phenotypic expression.
We also considered whether treatment with M7.8L could change the survival of the neonatal mutant transgenic mice. Thus, we compared neonatal mutant transgenic (mutTg) mice treated with the control virus 
AAV9 M7.8L therapy suppresses expression of CamKII and BrgI
We studied downstream effects of the RLC-47K variant on modulators of calcium dynamics and chromatin modification pathways since i) the RLC-47K variant is located in the calcium-binding site of the RLC ( Figure 4G) , ii) calcium is a critical mediator of cardiac hypertrophy and relaxation [15] [16] [17] , and iii) we demonstrated reversible changes in calcium kinetics previously and above 5, 6 . We prepared RNA and protein extracts from heart tissue from the neonatal experimental group to assess ATPase sarcoplasmic/endoplasmic reticulum calcium transporting 2 (ATP2A2), phospholamban (PLB), calmodulin-dependent protein kinase II (CAMKII) a and g isoforms and the cardiac ryanodine receptor (RYR2). Each was measured by quantitative PCR, RNA sequencing and western blot. qPCR and RNA sequencing studies showed that mRNA levels of SERCA2, Plb (Figure 4H-I) and RyR, CamKIIa and CamKIIg respectively (Support Figure 13G -H) were significantly decreased in the untreated groups consistent with a disease state. Treatment with AAV9 M7.8L increased the mRNA levels while protein levels of these markers remained largely unchanged (Support Figure 11 ) with the exception of CamKII. Protein levels of CamKII were increased in control and untreated mice but significantly reduced with AAV9 M7.8L treatment ( Figure 4J) . Increases in protein abundance of CamKII in control and untreated mice may be due to elevated intracellular calcium concentrations associated with the RLC-47K mutation.
We also explored mRNA and protein levels of the transcriptional activator Brg1. This catalytic subunit of chromatin-modifying enzyme complexes is a major regulator of transcription through the modulation of chromatin in various tissues and physiological conditions. We previously demonstrated a critical role in myocardial transcription in response to hypertrophic stimuli. 18 Consistent with our hypothesized role for chromatin remodeling in the downstream effects of RLC restrictive cardiomyopathy, Brg1 protein levels were modestly increased in the mutant mice. After silencing, Brg1 protein expression level was dramatically reduced ( Figure 4J ) while mRNA level was not significant ( Figure 4K) .
Effect on the myocardial transcriptional program including microRNAs RNA sequencing including small RNA profiling was used to assess i) the presence of delivered therapeutic, ii) effects on the mutant and wild type alleles, iii) gene expression network effects of disease and silencing, and iv) disruption of the native small RNA processing apparatus and microRNA function. Transcriptome analysis showed that M7.8L shRNA and CFP was highly expressed in the hearts of humanized mutant transgenic mice treated at 3 days old of age ( Figure 5A and 5B) and allele specific silencing 27% of the human MYL2-47K (RLC-47K) mutation ( Figure 5C ) without affecting the mouse endogenous myl2 gene ( Figure 5D ). miRNA profiling showed a pathological signature in untreated and control RLC-47K mice, with the upregulation of mir208a, and mir208b and downregulation of mir-499, which is a common response to cardiac injury [19] [20] [21] , however no significant changes were observed for mir208a and mir-499 in the M7.8L treated group compared to the untreated and control groups. On the other hand, the expression of mir208b was significantly downregulated in the treated group, which was consistent with a positive therapeutic benefit. This emphasizes the complexity of cardiac remodeling and the time-dependent nature of the changes in different signaling networks. (Figure 5E-G) . To assess downstream broader transcriptional effects of the treatment, we adopted a network approach similar to those we have previously published. [22] [23] [24] [25] [26] We obtained the top 30 differentially expressed genes between treated and control groups and extracted interacting genes and relationships from the STRING database. 27 We then plotted the resulting interaction network with each gene's expression fold change ( Figure 5H ). This visualization revealed reversal of the stress/remodeling myocardial gene program and related markers (including Myh7, Nppa, Nppb, Acta1) as well as up-regulation of gene networks that included acetyl-CoA transferases (Ech1, Ecl1, Acaa1, Figure   5I ), indicating a wide, systemic, transcriptional effect of the treatment in reverting the disease gene expression program.
Minimal impact of off-target delivery or endogenous RNA interference pathways
We assessed the expression level of the enzymes argonaute and dicer and found a slight increase of argonaute and no significant changes in the expression of dicer in the 3 days old treated mutant transgenic mice as compared to the untreated and control animals ( Figure 5J -K) suggesting that shRNA/miRNAshared pathways were modestly affected during four months of constitutive expression of M7.8L shRNA in the hearts of adult mice. These effects and the lack of in vivo cytotoxicity in RLC-4K treated mice are consistent with the effects of the H1 promoter that drives M7.8L shRNA expression in a more restrained manner than the U6 promoter 28, 29 . Similar findings have been observed in mouse liver after knockdown of hepatitis B virus with shRNA driven by weak promoters 30 .
Discussion
In the present study, we present data to support allele-specific silencing of the human N47K (Asn47Lys) mutation of the regulatory light chain (RLC) encoded by the MYL2 gene using an AAV-RNA interference approach. Allele specific silencing of the RLC-47K mutation was sufficient to reduce disease phenotypes such as cardiac fibrosis, heart weight, left ventricular mass and hypertrophic biomarkers, and increase survival. This work adds to the literature by presenting an agent that targets a human mutation and by demonstrating improvements in single cell kinetics, organ function, and survival, without significant disruption of endogenous small RNA processing.
We used a sequential strategy of siRNA screening followed by secondary testing of selected shRNAs before bundling of the most effective shRNA with AAV9 for in vivo delivery to the heart. Fluorescent protein knockdown in stable HEK cells by M7 siRNA was 50-65% for the mutant allele in contrast with the normal allele that was knocked down by less than 10%. M7.8L shRNA knockdown of the mutant allele was 70% (normal allele less by 10%), while in vivo allele-knockdown of MYL2-47K at 4 months was 27% by RNA sequencing (Figure 5C ). This sustained but modest reduction appeared sufficient to revert the disease phenotype during four months of observation without affecting the normal allele. In addition, we observed that shRNA expression declined after four months of treatment, however this course of treatment was sufficient to ameliorate the disease with minimal off-target effects, while efficacy when mice were treated at older age was reduced. In humans, there is often progression of disease seen during adolescence. Based on this observation it would seem that RNAi therapies should target early disease. However, some therapies, including the myosin ATPase inhibitor mavacamten and exercise, have suggested the possibility of reversal of cardiomyopathy phenotype even in adult mice.
These treatment effects are consistent with the previous report of allele-specific knockdown in HCM 2 where in vitro shRNA induced 80% knockdown of the mutant allele with 20% knockdown of the wild type allele in 293T cells. Corresponding knockdown of the deleterious allele in vivo was 28.5%. In one other study examining allele specific knockdown in catecholaminergic polymorphic ventricular tachycardia 31 the ratio between wild-type and mutant RYR2 mRNA was doubled from 1:1 to 2:1 after treatment suggesting a more robust change at the gene expression level, although total protein levels were reduced by 15%. The N47K mouse model, which has been previously reported as a model of hypertrophic cardiomyopathy, shows a phenotype in our hands most consistent with RCM. Phenotypic heterogeneity has been previously reported in heterozygous and homozygous sarcomeric mutations in both MYL2 and MYL3 genes 32, 33 . The model has the benefit of carrying a full human disease-associated transgene with a target sequence identical to the human mutated allele allowing modeling that can be directly translated to human therapeutics 5, 6, 34 . In addition, disease progression in this model is significant, which allowed a relatively short therapeutic treatment (4 months) compared to other reports in the alpha-MHC R403Q knock-in mouse that, although possessing the advantage of mimicking the allele stoichiometry of dominant disease, has the disadvantage of targeting the mouse Myh6 gene, something that cannot be directly translated to humans. In addition, the R403Q model requires a chemical trigger (cyclosporine A) or extensive aging to provoke hypertrophy, complicating the pathophysiology of resulting hypertrophy.
We first reported allele-specific knockdown of cardiomyopathy mutations in a preliminary report in 2010 35, 36 . In the intervening period, we are aware of only one published report demonstrating efficacy of this approach in vivo 2 . Another publication 31 referred to above used allele-specific silencing to treat CPVT with salutary benefits in mice. It is unclear why so few laboratories have focused an approach with such apparent potential for personalized therapeutics in an era of precision medicine. Major challenges remain in delivery, specificity, and efficacy. The first has been particularly challenging for cardiac delivery and there exists no approved cardiac genetic therapy at this time. Approved RNA silencing agents have taken advantage of strong uptake from organs such as the liver or eye. It is encouraging however that in each of the reports of therapeutic silencing in the heart, therapeutic efficacy seems to be established with between 25 and 50% relative knockdown of the mutant cardiac allele. While these reports cannot rule out a greater degree of silencing immediately post delivery it is a hopeful sign that long term effects can be achieved with a single administration. More recent reports of the therapeutic benefits of CRISPR-Cas systems for gene editing make the advances described here, and in other papers reporting non-allele specific approaches to genetic therapy [37] [38] [39] [40] , all the more important. Recent publications suggest that packaged CRISPR-Cpf1 delivery to skeletal muscle can be effective in abrogating the progression of muscular dystrophy 41 . In a report of gene editing of human embryos, 1 the disease at focus was hypertrophic cardiomyopathy, however the utility of this approach in postnatal humans is unproven.
Our work has limitations. While expression of a human transgene allows insight into the translation of such a therapy to humans, the presence of the native mouse genes in our animal model is not representative.
Potential human translation with AAV9 delivery may also be limited by pre-existing or triggered antibodies.
While patient-specific reagents would be expensive to produce, we 35, 42 and others 2 have discussed that while the causative variants for HCM and RCM are very rare (and so would require almost personalized therapy), common variants on the same allele as the causative rare variant are an attractive target for silencing. We have found using computational modeling that a panel of between 5 and 10 common variants per diseasecausative HCM gene would be enough to implement a silencing approach in any individual in the population. This is a much more tractable approach for human translation than generating a new individualized therapy for each patient as many families harbor so-called 'private mutations' not otherwise found in the world.
Despite these challenges, we are encouraged by the results described here. As a result of these efforts and collaborative work among the groups working in this area, we anticipate steady progress towards realization of genome-guided precision therapeutics for the many families affected by genetic cardiomyopathy.
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Figure 5
Gene expression and whole-transcriptome analysis of heart tissue isolated from mutant transgenic mice after 16 weeks of treatment with AAV9-M7.8L shRNA. Legend: UT, untreated mice; CTRL, mice treated with AAV9 non-expressing shRNA and M7.8L, mice treated with M7.8L shRNA. (A) RNA sequencing analysis (RNA-seq) of M7.8L shRNA showed a significant increase of expression in the treated group confirming the presence of the shRNA in the left ventricle (LV) of the heart tissue (UT vs M7.8L p=0.02400; CTRL vs M7.8L p=0.02400).(B) RNA-seq analysis of the cerulean reporter in the M7.8L treated group showed an increment of expression, which confirms successful transduction of the heart tissue by AAV9-M7.8L (UT vs M7.8L p=3.66x10 -11 ; CTRL vs M7.8L p= 3.66x10 -11 ). (C) RNA-seq analysis of the mutant allele in the treated group showed a decrement of 23% of the mutant allele versus the untreated and control groups (UT vs M7.8L p=0.00028; CTRL vs M7.8L p=0.00032), which was sufficient to revert the disease phenotype.
(D) RNA-seq analysis of the mouse endogenous MYL2 gene showed not significant changes in expression in the treated group versus the untreated and control groups (UT vs M7.8L p=0.05445; CTRL vs M7.8L p= 0.05704), which indicates the specificity of the shRNA. (E) RNA-seq analysis of the MYH7 modifier mir208a (UT vs M7.8L p=0.15346; CTRL vs M7.8L p=0.09018) showed no changes of expression versus the untreated and control groups. (F) while mir208b showed significant downregulation in the M7.8L treated group versus the untreated and control groups (M7.8LmutTg vs CTRL mutTg p=0.0013), however this is consistent with previous findings that indicate that mir208b can be detected in the adult heart at very low levels and it is only highly expressed during development. (G) mir499 showed no significant changes in gene expression compared to the untreated and control groups. (H) Gene-gene interaction network of top differentially expressed genes as derived from knowledge-based interactions from the STRING database, link color indicate confidence of interaction. The last two panels demonstrate a reversion of they hypertrophic gene expression program in the treated mice (not sentinel markers such as nppa, nppb and myh7 are downregulated). (I) Top differentially expressed genes (left) and miRNAs (right) in untreated, control and M7.8L shRNA treated. (J) RNA-seq analysis of the RNA interference processing enzyme AGO1 showed a significant but modest increase in expression compared to the untreated group, but not with the control group (UT vs M7.8L p=0.00139; CTRL vs M7.8L p=0.11881). (K) while DICER shows no significant changes in expression versus the untreated and control groups (UT vs M7.8L p= 0.07915; CTRL vs M7.8L p=0.08460). These findings suggest minimal effects on the RNA interference pathway.
